Cutia Therapeutics (HK:2487)
:2487
Want to see HK:2487 full AI Analyst Report?
Total Valuation
Cutia Therapeutics has a market cap or net worth of HK$1.68B. The enterprise value is HK$1.50B.
Market CapHK$1.68B
Enterprise ValueHK$1.50B
Share Statistics
Cutia Therapeutics has 364,730,870 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding364,730,870
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cutia Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -23.98%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-23.98%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee983.34K
Profits Per Employee-1.02M
Employee Count333
Asset Turnover0.25
Inventory Turnover5.01
Valuation Ratios
The current PE Ratio of Cutia Therapeutics is ―. Cutia Therapeutics’s PEG ratio is 0.14.
PE Ratio―
PS Ratio4.12
PB Ratio1.52
Price to Fair Value1.52
Price to FCF-4.45
Price to Operating Cash Flow-12.17
PEG Ratio0.14
Income Statement
In the last 12 months, Cutia Therapeutics had revenue of 327.45M and earned -331.39M in profits. Earnings per share was -1.01.
Revenue327.45M
Gross Profit149.58M
Operating Income-292.38M
Pretax Income-331.39M
Net Income-331.39M
EBITDA-251.23M
Earnings Per Share (EPS)-1.01
Cash Flow
In the last 12 months, operating cash flow was -119.63M and capital expenditures -3.26M, giving a free cash flow of -122.89M billion.
Operating Cash Flow-119.63M
Free Cash Flow-122.89M
Free Cash Flow per Share-0.34
Dividends & Yields
Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change-30.83%
50-Day Moving Average4.80
200-Day Moving Average7.02
Relative Strength Index (RSI)51.00
Average Volume (3m)399.60K
Important Dates
Cutia Therapeutics upcoming earnings date is Aug 27, 2026, Before Open (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateAug 27, 2026
Ex-Dividend Date―
Financial Position
Cutia Therapeutics as a current ratio of 3.87, with Debt / Equity ratio of 35.85%
Current Ratio3.87
Quick Ratio3.73
Debt to Market Cap0.19
Net Debt to EBITDA-0.21
Interest Coverage Ratio-30.90
Taxes
In the past 12 months, Cutia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cutia Therapeutics EV to EBITDA ratio is -5.58, with an EV/FCF ratio of -4.62.
EV to Sales4.28
EV to EBITDA-5.58
EV to Free Cash Flow-4.62
EV to Operating Cash Flow-4.83
Balance Sheet
Cutia Therapeutics has HK$789.16M in cash and marketable securities with HK$317.53M in debt, giving a net cash position of HK$471.64M billion.
Cash & Marketable SecuritiesHK$789.16M
Total DebtHK$317.53M
Net CashHK$471.64M
Net Cash Per ShareHK$1.29
Tangible Book Value Per ShareHK$2.70
Margins
Gross margin is 51.92%, with operating margin of -89.29%, and net profit margin of -101.20%.
Gross Margin51.92%
Operating Margin-89.29%
Pretax Margin-101.20%
Net Profit Margin-101.20%
EBITDA Margin-76.72%
EBIT Margin-89.29%
Analyst Forecast
The average price target for Cutia Therapeutics is HK$7.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$7.45
Price Target Upside62.31% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast20.92%
EPS Growth Forecast27.49%